GENEART AG Receives a Grant for the Targeted Design of Vaccine Candidates
7/10/2008 8:18:14 AM
Regensburg, July 10, 2008 - GENEART AG, the global leader in gene synthesis and specialist in the field of Synthetic Biology, participates in a joint project to develop a novel vaccine technology by designing a vaccine against the H5N1 avian influenza virus as a test case. GENEART receives a quarter of the total public project funding of about EUR 0.8M. The project offers GENEART another opportunity to advance the company's expertise in the conceptual design of safe and effective vaccines. Moreover, the project also feeds into the company's rapidly advancing work on the targeted design of proteins.